Syntax Bio Expands Series A to $14.4M, Total Funding Exceeds $25M
Syntax Bio expanded its Series A financing round to $14.4 million, bringing total funding raised to more than $25 million, the synthetic biology company announced Sunday. The company did not disclose new or existing investor participants, incremental round details, or uses of proceeds.
Syntax Bio expanded its Series A financing round to $14.4 million, bringing total funding raised to more than $25 million, the privately held synthetic biology company announced Sunday. The round included participation from existing investors, though the company did not disclose the incremental amount raised in the expansion or identify new participants.
Syntax Bio focuses on cell therapies using synthetic biology platforms. The company did not disclose valuation, the Series A initial close size, or the date of the original round. No leadership appointments or board additions were detailed in the available source material beyond a reference in the headline.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.